Pharming Group N.V.
PHGUF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -4.70 | 0.43 | -3.42 | -0.58 |
| FCF Yield | -1.00% | -2.36% | 2.79% | 3.79% |
| EV / EBITDA | 53.69 | 91.71 | 21.12 | 10.29 |
| Quality | ||||
| ROIC | -1.47% | -1.21% | 4.48% | 5.44% |
| Gross Margin | 80.75% | 89.72% | 90.91% | 89.37% |
| Cash Conversion Ratio | 0.21 | 1.81 | 1.53 | 1.64 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.06% | 8.92% | -3.44% | 0.09% |
| Free Cash Flow Growth | 64.17% | -189.70% | 3.73% | -72.93% |
| Safety | ||||
| Net Debt / EBITDA | 4.21 | 11.12 | -1.21 | -0.62 |
| Interest Coverage | -0.37 | -0.90 | 3.28 | 4.68 |
| Efficiency | ||||
| Inventory Turnover | 0.64 | 0.44 | 0.41 | 0.74 |
| Cash Conversion Cycle | 532.02 | 743.62 | 754.75 | 425.69 |